Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 424239, 14 pages
http://dx.doi.org/10.1155/2014/424239
Research Article

Novel Resveratrol and 5-Fluorouracil Coencapsulated in PEGylated Nanoliposomes Improve Chemotherapeutic Efficacy of Combination against Head and Neck Squamous Cell Carcinoma

1Centre for Nanotechnology & Advanced Biomaterials, School of Chemical and Biotechnology, SASTRA University, Thanjavur 613401, India
2AstraZeneca India Pvt. Ltd. Avishkar, Bellary Road, Hebbal, Bangalore 560024, India

Received 12 February 2014; Accepted 27 April 2014; Published 9 July 2014

Academic Editor: Yasuhiro Nakamura

Copyright © 2014 Aarti Mohan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Y. Holoye, R. M. Byers, D. A. Gard, H. Goepfert, O. M. Guillamondegui, and R. H. Jesse, “Combination chemotherapy of head and neck cancer,” Cancer, vol. 42, no. 4, pp. 1661–1669, 1978. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Bernier, C. Domenge, M. Ozsahin et al., “Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer,” The New England Journal of Medicine, vol. 350, pp. 1945–1952, 2004. View at Google Scholar
  3. F. Keil, E. Selzer, A. Berghold et al., “Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck,” European Journal of Cancer, vol. 49, no. 2, pp. 352–359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. J. H. Lorch, O. Goloubeva, R. I. Haddad et al., “Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial,” The Lancet Oncology, vol. 12, no. 2, pp. 153–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Rütten, L. A. M. Pop, G. O. R. J. Janssens et al., “Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic,” International Journal of Radiation Oncology, Biology, Physics, vol. 81, no. 4, pp. 923–929, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Merlano, E. Russi, M. Benasso et al., “Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study,” Annals of Oncology, vol. 22, no. 3, pp. 712–717, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. T. M. Allen and P. R. Cullis, “Liposomal drug delivery systems: From concept to clinical applications,” Advanced Drug Delivery Reviews, vol. 65, no. 1, pp. 36–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. H. I. Chang and M. K. Yeh, “Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy,” International Journal of Nanomedicine, vol. 7, pp. 49–60, 2012. View at Google Scholar · View at Scopus
  9. Y. Barenholz, “Doxil: the first FDA-approved nano-drug: lessons learned,” Journal of Controlled Release, vol. 160, no. 2, pp. 117–134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. G. P. Stathopoulos, “Liposomal cisplatin: a new cisplatin formulation,” Anti-Cancer Drugs, vol. 21, no. 8, pp. 732–736, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Boulikas, “Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin,” Expert Opinion on Investigational Drugs, vol. 18, no. 8, pp. 1197–1218, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. R. J. Kim, G. Peterson, B. Kulp, K. M. Zanotti, and M. Markman, “Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers,” Gynecologic Oncology, vol. 97, no. 2, pp. 374–378, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Slingerland, H. Guchelaar, and H. Gelderblom, “Liposomal drug formulations in cancer therapy: 15 years along the road,” Drug Discovery Today, vol. 17, no. 3-4, pp. 160–166, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Shankar, B. N. Singh, and R. K. Srivastava, “Plant polyphenols and their role in cancer prevention and chemotherapy,” in Nutrition, Diet and Cancer, S. Shankar and R. K. Srivastava, Eds., pp. 209–234, Springer, Berlin, Germany, 2012. View at Publisher · View at Google Scholar
  15. L. G. Korkina, S. Pastore, E. Dellambra, and C. de Luca, “New molecular and cellular targets for chemoprevention and treatment of skin tumors by plant polyphenols: a critical review,” Current Medicinal Chemistry, vol. 20, no. 7, pp. 852–868, 2013. View at Google Scholar · View at Scopus
  16. L. C. Thuc, Y. Teshima, N. Takahashi et al., “Inhibition of Na+-H+ exchange as a mechanism of rapid cardioprotection by resveratrol,” British Journal of Pharmacology, vol. 166, no. 6, pp. 1745–1755, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Li, N. Xia, and U. Förstermann, “Cardiovascular effects and molecular targets of resveratrol,” Nitric Oxide, vol. 26, no. 2, pp. 102–110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Tsai, F. Liu, Y. Lau, and H. Yu, “Role of Akt-dependent pathway in resveratrol-mediated cardioprotection after trauma-hemorrhage,” Journal of Surgical Research, vol. 176, no. 1, pp. 171–177, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Wang, Q. Bo, X. Zhao, X. Yang, Z. Chi, and X. Liu, “Resveratrol pre-treatment reduces early inflammatory responses induced by status epilepticus via mTOR signaling,” Brain Research, vol. 1492, pp. 122–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. M. U. Nessa, P. Beale, C. Chan, J. Q. Yu, and F. Huq, “Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells,” Anticancer Research, vol. 32, no. 1, pp. 53–59, 2012. View at Google Scholar · View at Scopus
  21. T. Erdem, T. Bayindir, A. Filiz, M. Iraz, and E. Selimoglu, “The effect of resveratrol on the prevention of cisplatin ototoxicity,” European Archives of Oto-Rhino-Laryngology, vol. 269, no. 10, pp. 2185–2188, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Dudka, R. Gieroba, A. Korga et al., “Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 606183, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Scott, W. P. Steward, A. J. Gescher, and K. Brown, “Resveratrol in human cancer chemoprevention—choosing the “right” dose,” Molecular Nutrition and Food Research, vol. 56, no. 1, pp. 7–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Tome-Carneiro, M. Larrosa, A. Gonzalez-Sarrias, F. A. Tomas-Barberan, M. T. Garcia-Conesa, and J. C. Espin, “Resveratrol and clinical trials: the crossroads from in vitro studies to human evidence,” Current Pharmaceutical Design, vol. 19, pp. 6064–6093, 2013. View at Google Scholar
  25. J. Y. Chan, S. P. Meng, M. V. Clement, S. Pervaiz, and C. L. Shao, “Resveratrol displays converse dose-related effects on 5-fluorouracilevoked colon cancer cell apoptosis: the roles of caspase-6 and p53,” Cancer Biology and Therapy, vol. 7, no. 8, pp. 1305–1312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Mohapatra, R. Preet, M. Choudhuri, T. Choudhuri, and C. N. Kundu, “5-Fluorouracil increases the chemopreventive potentials of resveratrol through DNA damage and MAPK signaling pathway in human colorectal cancer cells,” Oncology Research, vol. 19, no. 7, pp. 311–321, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. S. L. Wu, Z. J. Sun, L. Yu, K. W. Meng, X. L. Qin, and C. E. Pan, “Effect of resveratrol and in combination with 5-FU on murine liver cancer,” World Journal of Gastroenterology, vol. 10, no. 20, pp. 3048–3052, 2004. View at Google Scholar · View at Scopus
  28. M. Singh, P. Bhatnagar, A. K. Srivastava, P. Kumar, Y. Shukla, and K. C. Gupta, “Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles,” Journal of Biomedical Nanotechnology, vol. 7, no. 1, article 202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Wong and G. N. C. Chiu, “Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model,” Nanomedicine, vol. 7, no. 6, pp. 834–840, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Mulherkar, A. P. Goud, A. S. Wagle et al., “Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract,” Cancer Letters, vol. 118, no. 1, pp. 115–121, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. R. C. Mashru, V. B. Sutariya, M. G. Sankalia, and P. P. Parikh, “Development and evaluation of fast-dissolving film of salbutamol suplhate,” Drug Development and Industrial Pharmacy, vol. 31, no. 1, pp. 25–34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. M. C. Gohel, R. K. Parikh, P. Y. Aghara, S. A. Nagori, R. R. Delvadia, and M. R. Dabhi, “Application of simplex lattice design and desirability function for the formulation development of mouth dissolving film of salbutamol sulphate,” Current Drug Delivery, vol. 6, no. 5, pp. 486–494, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Voigt, Methods Molecular Medicine, vol. 110 of edited by R. D. Blumenthal, Springer, New York, NY, USA, 2005.
  34. T. C. Chou, “Theoretical basis, experimental design and computerized simulation of synergism and antagonism in drug combination studies,” Pharmacological Reviews, vol. 58, no. 3, pp. 621–681, 2006. View at Publisher · View at Google Scholar
  35. M. L. Immordino, F. Dosio, and L. Cattel, “Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential,” International Journal of Nanomedicine, vol. 1, no. 3, pp. 297–315, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Maruyama, “Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects,” Advanced Drug Delivery Reviews, vol. 63, no. 3, pp. 161–169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Maruyama, T. Yuda, A. Okamoto, S. Kojima, A. Suginaka, and M. Iwatsuru, “Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol),” Biochimica et Biophysica Acta, vol. 1128, no. 1, pp. 44–49, 1992. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Mac Lachlan, “Liposomal formulations for nucleic acid delivery,” in Antisense Drug Technology: Principles, Strategies and Applications, S. T. Crooke, Ed., vol. 9, CRC Press, Boca Raton, Fla, USA, 2008. View at Google Scholar
  39. C. Demetzos, “Differential Scanning Calorimetry (DSC): a tool to study the thermal behavior of lipid bilayers and liposomal stability,” Journal of Liposome Research, vol. 18, no. 3, pp. 159–173, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Fabris, F. Momo, G. Ravagnan, and R. Stevanato, “Antioxidant properties of resveratrol and piceid on lipid peroxidation in micelles and monolamellar liposomes,” Biophysical Chemistry, vol. 135, no. 1–3, pp. 76–83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. G. Sarpietro, C. Spatafora, C. Tringali, D. Micieli, and F. Castelli, “Interaction of resveratrol and its trimethyl and triacetyl derivatives with biomembrane models studied by differential scanning calorimetry,” Journal of Agricultural and Food Chemistry, vol. 55, no. 9, pp. 3720–3728, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. O. Wesołowska, M. Kuzdzał, J. Štrancar, and K. Michalak, “Interaction of the chemopreventive agent resveratrol and its metabolite, piceatannol, with model membranes,” Biochimica et Biophysica Acta: Biomembranes, vol. 1788, no. 9, pp. 1851–1860, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Brittes, M. Lúcio, C. Nunes, J. L. F. C. Lima, and S. Reis, “Effects of resveratrol on membrane biophysical properties: relevance for its pharmacological effects,” Chemistry and Physics of Lipids, vol. 163, no. 8, pp. 747–754, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Selvaraj, A. Mohan, S. Narayanan, S. Sethuraman, and U. M. Krishnan, “Dose-dependent interaction of trans-resveratrol with biomembranes: effects on antioxidant property,” Journal of Medicinal Chemistry, vol. 56, no. 3, pp. 970–981, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Auger, “Biological membrane structure by solid-state NMR.,” Current issues in molecular biology, vol. 2, no. 4, pp. 119–124, 2000. View at Google Scholar · View at Scopus
  46. A. U. Gjerde, H. Holmsen, and W. Nerdal, “Chlorpromazine interaction with phosphatidylserines: a 13C and 31P solid-state NMR study,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1682, no. 1–3, pp. 28–37, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. G. M. M. El Maghraby, A. C. Williams, and B. W. Barry, “Drug interaction and location in liposomes: correlation with polar surface areas,” International Journal of Pharmaceutics, vol. 292, no. 1-2, pp. 179–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Okamura and N. Yoshii, “Drug binding and mobility relating to the thermal fluctuation in fluid lipid membranes,” The Journal of Chemical Physics, vol. 129, no. 21, Article ID 215102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. G. A. Georgiev, D. K. Sarker, O. Al-Hanbali, G. D. Georgiev, and Z. Lalchev, “Effects of poly (ethylene glycol) chains conformational transition on the properties of mixed DMPC/DMPE-PEG thin liquid films and monolayers,” Colloids and Surfaces B: Biointerfaces, vol. 59, no. 2, pp. 184–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Sabín, G. Prieto, J. M. Ruso, R. Hidalgo-Álvarez, and F. Sarmiento, “Size and stability of liposomes: a possible role of hydration and osmotic forces,” The European Physical Journal E, vol. 20, no. 4, pp. 401–408, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Garcia-Manyes, G. Oncins, and F. Sanz, “Effect of ion-binding and chemical phospholipid structure on the nanomechanics of lipid bilayers studied by force spectroscopy,” Biophysical Journal, vol. 89, no. 3, pp. 1812–1826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. T. Cserháti and M. Szögyi, “Interaction between phospholipids and monovalent cations studied by a new thin-layer chromatographic method,” Chemistry and Physics of Lipids, vol. 34, no. 1, pp. 93–99, 1983. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Costa and J. M. Sousa Lobo, “Modeling and comparison of dissolution profiles,” European Journal of Pharmaceutical Sciences, vol. 13, no. 2, pp. 123–133, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Glavas-Dodov, E. Fredro-Kumbaradzi, K. Goracinova, S. Calis, M. Simonoska, and A. A. Hincal, “5-Fluorouracil in topical liposome gels for anticancer treatment—formulation and evaluation,” Acta Pharmaceutica, vol. 53, no. 4, pp. 241–250, 2003. View at Google Scholar · View at Scopus
  55. T. Chou, “Drug combination studies and their synergy quantification using the chou-talalay method,” Cancer Research, vol. 70, no. 2, pp. 440–446, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Chou and P. Talalay, “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors,” Advances in Enzyme Regulation, vol. 22, pp. 27–55, 1984. View at Publisher · View at Google Scholar · View at Scopus
  57. T. C. Chou, “Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro,” Contributions to Gynecology and Obstetrics, vol. 19, pp. 91–107, 1994. View at Google Scholar · View at Scopus
  58. R. J. Tallarida, “Revisiting the isobole and related quantitative methods for assessing drug synergism,” Journal of Pharmacology and Experimental Therapeutics, vol. 342, no. 1, pp. 2–8, 2012. View at Publisher · View at Google Scholar · View at Scopus